Polyvinylpyrrolidone (PVP) is a conventionally applied hydrophilic lubricious coating on catheter-based cardiovascular devices, used in order to ease movement through the vasculature. Its use as drug reservoir and transfer agent on drug-coated balloons (DCB) is therefore extremely promising with regard to the simplification of its approval as a medical device. Here, we developed a PVP-based coating for DCB, containing paclitaxel (PTX) as a model drug, and studied the impact of crosslinking via UV radiation on drug stability, wash off, and transfer during simulated use in an in vitro vessel model. We showed that crosslinking was essential for coating stability and needed to be performed prior to PTX incorporation due to decreased drug bioavailability as a result of photodecomposition and/or involvement in vinylic polymerization with PVP under UV radiation. Moreover, the crosslinking time needed to be carefully controlled. While short radiation times did not provide enough coating stability, associated with high wash off rates during DCB insertion, long radiation times lowered drug transfer efficiency upon balloon expansion. A ten minutes radiation of PVP, however, combined a minimized drug wash off rate of 34% with an efficient drug transfer of 49%, underlining the high potential of photochemically crosslinked PVP as a coating matrix for DCB.
References
[1]
Deloose, K.; Lauwers, K.; Callaert, J.; Maene, L.; Keirse, K.; Verbist, J.; Peeters, P.; Bosiers, M. Drug-eluting technologies in femoral artery lesions. J. Cardiovasc. Surg. 2013, 54, 217–224.
[2]
Buechel, R.; Stirnimann, A.; Zimmer, R.; Keo, H.; Groechenig, E. Drug-eluting stents and drug-coated balloons in peripheral artery disease. VASA 2012, 41, 248–261, doi:10.1024/0301-1526/a000200.
[3]
De Labriolle, A.; Pakala, R.; Bonello, L.; Lemesle, G.; Scheinowitz, M.; Waksman, R. Paclitaxel-eluting balloon: From bench to bed. Catheter. Cardiovasc. Interv. 2009, 73, 643–652, doi:10.1002/ccd.21895.
[4]
Waksman, R.; Pakala, R. Drug-eluting balloon: The comeback kid? Circ. Cardiovasc. Interv. 2009, 2, 352–358, doi:10.1161/CIRCINTERVENTIONS.109.873703.
[5]
Baumbach, A.; Herdeg, C.; Kluge, M.; Oberhoff, M.; Lerch, M.; Haase, K.K.; Wolter, C.; Schr？der, S.; Karsch, K.R. Local drug delivery: Impact of pressure, substance characteristics, and stenting on drug transfer into the arterial wall. Catheter. Cardiovasc. Interv. 1999, 47, 102–106, doi:10.1002/(SICI)1522-726X(199905)47:1<102::AID-CCD22>3.0.CO;2-G.
[6]
Scheller, B.; Speck, U.; Romeike, B.; Schmitt, A.; Sovak, M.; B？hm, M.; Stoll, H.-P. Contrast media as carriers for local drug delivery successful inhibition of neointimal proliferation in the porcine coronary stent model. Eur. Heart. J. 2003, 24, 1462–1467, doi:10.1016/S0195-668X(03)00317-8.
[7]
Cremers, B.; Clever, Y.; Schaffner, S.; Speck, U.; B？hm, M.; Scheller, B. Treatment of coronary in-stent restenosis with a novel paclitaxel urea coated balloon. Minerva Cardioangiol. 2010, 58, 583–588.
[8]
Joner, M.; Byrne, R.A.; Lapointe, J.-M.; Radke, P.W.; Bayer, G.; Steigerwald, K.; Wittchow, E. Comparative assessment of drug-eluting balloons in an advanced porcine model of coronary restenosis. Thromb. Haemost. 2011, 105, 864–872, doi:10.1160/TH10-11-0698.
[9]
Cortese, B.; Bertoletti, A. Paclitaxel coated balloons for coronary artery interventions: A comprehensive review of preclinical and clinical data. Int. J. Cardiol. 2012, 161, 4–12, doi:10.1016/j.ijcard.2011.08.855.
[10]
Sternberg, K.; Grabow, N.; Petersen, S.; Weitschies, W.; Harder, C.; Ince, H.; Kroemer, H.K.; Schmitz, K.-P. Advances in coronary stent technology—Active drug-loaded stent surfaces for prevention of restenosis and improvement of biocompatibility. Curr. Pharm. Biotechnol. 2013, 14, 76–90.
[11]
Kelsch, B.; Scheller, B.; Biedermann, M.; Clever, Y.P.; Schaffner, S.; Mahnkopf, D.; Speck, U.; Cremers, B. Dose response to Paclitaxel-coated balloon catheters in the porcine coronary overstretch and stent implantation model. Invest. Radiol. 2011, 46, 255–263, doi:10.1097/RLI.0b013e31820577df.
Kallmes, D.F.; McGraw, J.K.; Evans, A.J.; Mathis, J.M.; Hergenrother, R.W.; Jensen, M.E.; Cloft, H.J.; Lopes, M.; Dion, J.E. Thrombogenicity of hydrophilic and nonhydrophilic microcatheters and guiding catheters. AJNR Am. J. Neuroradiol. 1997, 18, 1243–1251.
[14]
Nagaoka, S.; Akashi, R. Low-friction hydrophilic surface for medical devices. Biomaterials 1990, 11, 419–424, doi:10.1016/0142-9612(90)90098-B.
[15]
Babcock, D.E.; Hergenrother, R.W.; Craig, D.A.; Kolodgie, F.D.; Virmani, R. In vivo distribution of particulate matter from coated angioplasty balloon catheters. Biomaterials 2013, 34, 3196–3205, doi:10.1016/j.biomaterials.2013.01.040.
[16]
Robinson, B.V. PVP: A Critical Review of the Kinetics and Toxicology of Polyvinylprrolidone (Povidone); Taylor & Francis: London, UK, 1990.
[17]
Barros, J.A.G.; Fechine, G.J.M.; Alcantara, M.R.; Catalani, L.H. Poly(N-vinyl-2-pyrrolidone) hydrogels produced by Fenton reaction. Polymer 2006, 47, 8414–8419, doi:10.1016/j.polymer.2006.10.033.
[18]
Rosiak, J.; Olejniczak, J.; P？kala, W. Fast reaction of irradiated polymers—I. Crosslinking and degradation of polyvinylpyrrolidone. Int. J. Radiat. Appl. Instrum. C 1990, 36, 747–755.
[19]
Henglein, A. Crosslinking of polymers in solution under the influence of gamma radiation. J. Phys. Chem. 1959, 63, 1852–1858, doi:10.1021/j150581a016.
[20]
Lopérgolo, L.C.; Lug？o, A.B.; Catalani, L.H. Direct UV photocrosslinking of poly(N-vinyl-2-pyrrolidone) (PVP) to produce hydrogels. Polymer 2003, 44, 6217–6222, doi:10.1016/S0032-3861(03)00686-4.
[21]
Speck, U.; Scheller, B.; Abramjuk, C.; Breitwieser, C.; Dobberstein, J.; Boehm, M.; Hamm, B. Neointima inhibition: Comparison of effectiveness of non–stent-based local drug delivery and a drug-eluting stent in porcine coronary arteries1. Radiology 2006, 240, 411–418, doi:10.1148/radiol.2402051248.
[22]
Scheller, B.; Hehrlein, C.; Bocksch, W.; Rutsch, W.; Haghi, D.; Dietz, U.; B？hm, M.; Speck, U. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N. Engl. J. Med. 2006, 355, 2113–2124, doi:10.1056/NEJMoa061254.
[23]
Scheller, B.; Hehrlein, C.; Bocksch, W.; Rutsch, W.; Haghi, D.; Dietz, U.; B？hm, M.; Speck, U. Two year follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. Clin. Res. Cardiol. 2008, 97, 773–781, doi:10.1007/s00392-008-0682-5.
[24]
Schmidt, W.; Lanzer, P. Instrumentation. In Catheter-Based Cardiovascular Interventions; Lanzer, P., Ed.; Springer: Berlin/Heidelberg, Germany, 2013; pp. 445–472.
[25]
T？nnesen, H.H. The Photostability of Drugs and Drug Formulations; Taylor & Francis: London, UK, 1996.
[26]
Chen, S.-H.; Farina, V.; Huang, S.; Gao, Q.; Golik, J.; Doyle, T.W. Studies on the photochemistry of taxol？. Tetrahedron 1994, 50, 8633–8650, doi:10.1016/S0040-4020(01)85337-0.
[27]
Petersen, S.; Kaule, S.; Stein, F.; Minrath, I.; Schmitz, K.-P.; Kragl, U.; Sternberg, K. Novel paclitaxel-coated angioplasty balloon catheter based on cetylpyridinium salicylate: Preparation, characterization and simulated use in an in vitro vessel model. Mater. Sci. Eng. C 2013, 33, 4244–4250, doi:10.1016/j.msec.2013.06.021.
[28]
Petersen, S.; Kaule, S.; Teske, M.; Minrath, I.; Schmitz, K.-P.; Sternberg, K. Development and in vitro characterization of hyaluronic acid-based coatings for implant-associated local drug delivery systems. J. Chem. 2013, 2013, 587875:1–587875:11.
[29]
Hoffman, A.S. Hydrogels for biomedical applications. Adv. Drug Deliv. Rev. 2012, 64, S18–S23, doi:10.1016/j.addr.2012.09.010.
[30]
Scheller, B.; Speck, U.; Abramjuk, C.; Bernhardt, U.; B？hm, M.; Nickenig, G. Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis. Circulation 2004, 110, 810–814, doi:10.1161/01.CIR.0000138929.71660.E0.
